Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Beats Revenue Estimates
Avidity Biosciences (RNA) delivered earnings and revenue surprises of -20.95% and +399.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?